β-secretase inhibitor; a promising novel therapeutic drug in Alzheimer's disease
about
Therapies for Prevention and Treatment of Alzheimer's DiseaseCurrent Research Therapeutic Strategies for Alzheimer's Disease TreatmentFluid Biomarkers in Clinical Trials of Alzheimer's Disease TherapeuticsAnti-dementia medications: current prescriptions in clinical practice and new agents in progressBACE1 across species: a comparison of the in vivo consequences of BACE1 deletion in mice and rats1950 MHz Electromagnetic Fields Ameliorate Aβ Pathology in Alzheimer's Disease MiceRole of amyloid peptides in vascular dysfunction and platelet dysregulation in Alzheimer's diseaseElectroacupuncture Reduces Aβ Production and BACE1 Expression in SAMP8 Mice.Overexpression of Swedish mutant APP in aged astrocytes attenuates excitatory synaptic transmissionNeurological dysfunctions associated with altered BACE1-dependent Neuregulin-1 signaling.Molecular Docking and In Silico ADMET Study Reveals Acylguanidine 7a as a Potential Inhibitor of β-SecretaseAZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics.Sodium selenate regulates the brain ionome in a transgenic mouse model of Alzheimer's disease.Preclinical to phase II amyloid beta (Aβ) peptide modulators under investigation for Alzheimer's disease.Targeting Tumor Necrosis Factor Alpha for Alzheimer's Disease.Rhizophora mucronata attenuates beta-amyloid induced cognitive dysfunction, oxidative stress and cholinergic deficit in Alzheimer's disease animal model.Alzheimer's disease drug development pipeline: 2017.Alzheimer's drug-development pipeline: 2016.PLGA nanoparticles modified with a BBB-penetrating peptide co-delivering Aβ generation inhibitor and curcumin attenuate memory deficits and neuropathology in Alzheimer's disease mice.Clinical Bioavailability of the Novel BACE1 Inhibitor Lanabecestat (AZD3293): Assessment of Tablet Formulations Versus an Oral Solution and the Impact of Gastric pH on Pharmacokinetics.Population density analysis for determining the protonation state of the catalytic dyad in BACE1-tertiary carbinamine-based inhibitor complex.A microfluidics-based mobility shift assay to identify new inhibitors of β-secretase for Alzheimer's disease.Effects of senescence and angiotensin II on expression and processing of amyloid precursor protein in human cerebral microvascular endothelial cells.RAGE mediates Aβ accumulation in a mouse model of Alzheimer's disease via modulation of β- and γ-secretase activity.Prospects of β-Secretase Inhibitors for the Treatment of Alzheimer's Disease.Simultaneous quantitation of the BACE1 inhibitor AZD3293 and its metabolite AZ13569724 in human matrices by LC-MS/MS.BACE1 Inhibitor Lanabecestat (AZD3293) in a Phase 1 Study of Healthy Japanese Subjects: Pharmacokinetics and Effects on Plasma and Cerebrospinal Fluid Aβ Peptides.Protein Expression of BACE1 is Downregulated by Donepezil in Alzheimer's Disease Platelets.AZD3293: Pharmacokinetic and Pharmacodynamic Effects in Healthy Subjects and Patients with Alzheimer's Disease.The Role of microRNAs in Alzheimer's Disease and Their Therapeutic Potentials.Highlights in BACE1 Inhibitors for Alzheimer's Disease Treatment.
P2860
Q26740007-F0C87339-C890-4587-85F7-8F62E0E98D21Q26765530-9CF698E1-AAC7-4BCA-87F1-EE804966FA35Q26784569-B0D80DC6-5FE1-4800-8361-16246CBAD0CDQ26795400-060682D2-9F63-41F9-90A2-2CA7A0DB5148Q30361192-58704EED-EC31-464F-975A-F41A8EFC1D6EQ30853613-95670B4A-CE62-47EC-B94D-67EBBE087ED3Q35141182-FB8AA60F-F984-4E95-A9B5-231EE9EBA123Q35898132-3A9EA13C-537C-4F01-A91F-3BA0AAED3D8BQ36597696-70249446-8FB7-4BB9-AA54-BD754B09CD56Q36804007-55C3C528-C7E9-4B3A-B141-102CEBEA81FEQ36828224-B6AC2AED-026C-42B1-94E2-F2754930112EQ37053876-B37C6CB2-2FF9-4483-B1AA-B291F943FD38Q37529391-DBDA090C-434C-4D68-8BB3-184213621E72Q38864839-08ABC279-5AEC-479F-852E-DA11A2C6F40BQ38970893-02A30176-013E-4E95-A0D0-049D52C4F58DQ39759653-46D8836C-6CB6-40D4-B918-D4D16BA2E6D3Q42655757-E95316E3-52AD-4316-93BE-FBC86EA7EA58Q42656263-725A92AB-83E1-45D8-8325-07F239062029Q43980757-BE2523C3-77FF-49E3-BF48-1058AAAEC098Q47555674-2AFF7F42-F542-47FD-A73C-7CFE32012528Q47625268-58AA047D-5C9F-42FE-AA10-2AE2305DAD22Q47827489-3E2CD95D-9151-4FC2-A540-9016C196ABDBQ47853250-1174222E-536E-45E6-8F77-6CB99CE9E133Q47867340-AF353815-913A-4927-904A-35FD8ED614BCQ48096110-4468E10E-B862-4425-B833-FE8CDFD28D19Q50707800-E95B3D5C-DA46-4416-8816-DF445865ADECQ50943210-4A043A69-FB58-46CF-9EE5-74AEB46DAB0DQ51061879-0875003B-BD85-4FC7-86C3-C4DDCC0C0539Q51371177-AB70AA21-3012-4E58-B030-DD338EA308E0Q51760979-F4307A3C-84BF-4218-BC91-A4124313D778Q54940167-4181BE79-FDBB-47BC-B939-BF3CA1F91324
P2860
β-secretase inhibitor; a promising novel therapeutic drug in Alzheimer's disease
description
2014 nî lūn-bûn
@nan
2014 թուականին հրատարակուած գիտական յօդուած
@hyw
2014 թվականին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
β-secretase inhibitor; a promising novel therapeutic drug in Alzheimer's disease
@ast
β-secretase inhibitor; a promising novel therapeutic drug in Alzheimer's disease
@en
β-secretase inhibitor; a promising novel therapeutic drug in Alzheimer's disease
@nl
type
label
β-secretase inhibitor; a promising novel therapeutic drug in Alzheimer's disease
@ast
β-secretase inhibitor; a promising novel therapeutic drug in Alzheimer's disease
@en
β-secretase inhibitor; a promising novel therapeutic drug in Alzheimer's disease
@nl
prefLabel
β-secretase inhibitor; a promising novel therapeutic drug in Alzheimer's disease
@ast
β-secretase inhibitor; a promising novel therapeutic drug in Alzheimer's disease
@en
β-secretase inhibitor; a promising novel therapeutic drug in Alzheimer's disease
@nl
P2860
P3181
P356
P1476
β-secretase inhibitor; a promising novel therapeutic drug in Alzheimer's disease
@en
P2093
Jurgen A H R Claassen
Kelly Willemijn Menting
P2860
P3181
P356
10.3389/FNAGI.2014.00165
P407
P577
2014-01-01T00:00:00Z